A monoclonal antibody treatment (brand name REGEN-COV) has been authorized for emergency use by the FDA for patients 12 years of age and older in two situations:

  1. Treatment of mild to moderate coronavirus disease 2019 (COVID-19) in people who are at high risk of progression to severe COVID-19, including hospitalization or death.
  2. Prevention of COVID-19 in people who:
    1. are at high risk of progression to severe COVID-19, including hospitalization or death, AND
    2. are either not fully vaccinated or are not expected to mount an adequate immune response (for example, immunocompromised people) AND
    3. were exposed to someone infected with SARS-CoV-2 (the virus that causes COVID-19) as a close contact OR are at high risk of exposure to someone with SARS-CoV-2 infection in an institutional setting (for example, nursing homes and prisons)

If either of those situations apply to you, please see a healthcare provider for further information to see if you qualify for this monoclonal antibody treatment. This treatment is NOT authorized for use in patients who are already hospitalized and/or require oxygen therapy because of COVID-19.

Healthcare providers: see REGEN-COV fact sheet from Regeneron Pharmaceuticals here for more detailed information about authorized uses, limitations, dosage, and safety.

Note: The CDC recommends waiting at least 90 days after receiving monoclonal antibody COVID-19 treatment before getting a COVID-19 vaccine.